|[March 08, 2013]
Research and Markets: Eligard (Prostate Cancer) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/sfmjtg/eligard_prostate)
has announced the addition of GlobalData's new report "Eligard (Prostate
Cancer) - Forecast and Market Analysis to 2022" to their offering.
GlobalData has released its new PharmaPoint Drug Evaluation report,
Eligard (Prostate Cancer) - Forecast and Market Analysis to 2022. The
recent approvals of second-line metastatic castration-resistant prostate
cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and
Medivation/Astellas' Xtandi (enzalutamide) will drive strong market
growth over the next decade. These safe and orally administered
treatments will provide safety and convenience benefits over the current
standard of care, chemotherapy with docetaxel, while prolonging the
overall survival of patients with mCRPC.
The December 12, 2012 FDA approval of Zytiga for the added indication of
chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for
the disese, in which chemotherapy is relegated to second-line therapy
and beyond. For patients with earlier-stage prostate cancer, androgen
deprivation therapy with LHRH agonists and first-generation
antiandrogens remains the standard of care for suppressing testosterone
levels and temporarily controlling the disease.
Eligard was originally developed by QLT. It it's a super generic of
Abbott's and Takeda's Lupron Depot. Eligard was divested to Tolmar in
2009, and is currently marketed by Sanofi (US, Canada), Astellas Pharma
(5EU) and Hospira (Australia). Eligard is an LHRH agonist, which blocks
the release of luteinizing hormone and the subsequent release of
testosterone from the testes. It is used in ADT to control advanced
prostate cancer by achieving castrate levels of testosterone.
Like all LHRH agonists, Eligard is most commonly used in the treatment
of locally advanced and metastatic prostate cancer, sometimes in
combination with an antiandrogen like Casodex to achieve a CAB. Like all
hormone therapies, patients will eventually develop resistance, and
Eligard will no longer be able to control the disease. Even after the
cancer has become castration resistant, LHRH analogues like Eligard are
still used in combination with chemotherapy or targeted therapy in order
to maintain castrate levels of testosterone and best manage the disease.
- Overview of Prostate cancer, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Detailed information on Eligard including product description, safety
and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Eligard for the top nine countries from 2012 to
- Sales information covered for the US, Japan, UK, France, Germany,
Spain, Italy , Canada, and Australia
For more information visit http://www.researchandmarkets.com/research/sfmjtg/eligard_prostate
Source (News - Alert): GlobalData
[ Back To Technology News's Homepage ]